Ponoi Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Ponoi Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17M	Hold	1,298,908	–	–	23.2%	2
2022 Q2	$16.7M	Hold	1,298,908	–	–	26.29%	2
2022 Q1	$19.8M	Hold	1,298,908	–	–	25.71%	2
2021 Q4	$23M	Hold	1,298,908	–	–	21.21%	2
2021 Q3	$27.3M	Hold	1,298,908	–	–	24.24%	2
2021 Q2	$25.6M	Hold	1,298,908	–	–	14.23%	3
2021 Q1	$37.8M	Hold	1,298,908	–	–	22.21%	2
2020 Q4	$39.4M	Buy	+1,298,908	New	+$28.4M	22.52%	2

Other funds holding NGM

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ponoi Management's NGM Position: Q3 2022 in Review

Ponoi Management held its NGM Biopharmaceuticals, Inc. Common Stock (NGM) position steady in Q3 2022 at 1,298,908 shares worth $17M. The position accounts for 23.2% of the portfolio, ranked #2.

Ponoi Management first reported a position in NGM in Q4 2020 and has held it in 8 quarters since. The position peaked at $39.4M in Q4 2020. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

Ponoi Management held 1,298,908 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $17M as of Q3 2022.
Ponoi Management left its NGM Biopharmaceuticals, Inc. Common Stock share count unchanged in Q3 2022.
NGM Biopharmaceuticals, Inc. Common Stock made up 23.2% of Ponoi Management's portfolio in Q3 2022, its #2 holding.
Ponoi Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and has held it in 8 quarters since.
Ponoi Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $39.4M in Q4 2020.
128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Ponoi Management's 13F filing for Q3 2022, filed 14 Nov 2022.